This is a preview of subscription content, log in via an institution to check access.
Reference
Courtney PT, et al. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Network Open : 3 May 2021. Available from: URL: http://dx.doi.org/10.1001/jamanetworkopen.2021.8787
Rights and permissions
About this article
Cite this article
Nivolumab-ipilimumab not cost effective for advanced non-small-cell lung cancer in the US. PharmacoEcon Outcomes News 878, 20 (2021). https://doi.org/10.1007/s40274-021-7706-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7706-z